ASCL2 and glioma: The results showed that intragastric administration of ROC‐325 also prolonged the survival time of mice bearing ASCL2‐ATG9B AxisHigh glioma cells without significant toxicity (Figure 6K,L; and Figure S7B, Supporting Information).